COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00287898
Recruitment Status : Completed
First Posted : February 7, 2006
Last Update Posted : April 7, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Georgetown University

Brief Summary:

RATIONALE: Genetic counseling may work as well over the telephone as it does in-person. It is not yet known whether genetic counseling by telephone is more effective than standard (in-person) genetic counseling in women at risk of carrying the BRCA1 or BRCA2 mutation.

PURPOSE: This randomized phase III trial is studying telephone-based genetic counseling to see how well it works compared to standard (in-person) genetic counseling in women at risk of carrying the BRCA1 or BRCA2 mutation.

Condition or disease Intervention/treatment Phase
Breast Cancer Behavioral: Telephone Genetic Counseling Behavioral: Usual Care Not Applicable

Detailed Description:



  • Compare the impact of telephone genetic counseling (TGC) versus standard genetic counseling (SGC) on utilization of BRCA1/BRCA2 testing in women at risk of carrying the BRCA1/BRCA2 mutation.
  • Compare the relative efficacy of TGC versus SGC on satisfaction with the counseling process, informed decision making, psychosocial distress, and quality of life.


  • Identify participant characteristics that predict differential response to TGC.
  • Explore the mechanisms by which TGC or SGC impact distress and quality of life.

OUTLINE: This is a randomized, multicenter study. Participants are stratified according to participating site. Participants are randomized to 1 of 2 groups.

  • Group 1 (standard genetic counseling): Participants undergo an in-person genetic counseling session. Participants are then given the option of providing blood for genetic testing at the study site. Participants who choose to undergo genetic testing receive their results in-person from their genetic counselor.
  • Group 2 (telephone-based genetic counseling): Participants undergo a telephone-based genetic counseling session. Participants who choose to undergo genetic testing receive a pre-labeled blood kit in the mail. Participants receive their results over the phone from their genetic counselor.

After completion of genetic counseling, all participants are followed periodically for 1 year.

PROJECTED ACCRUAL: A total of 600 participants will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 669 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Telephone-Based Genetic Counseling; An Equivalence Trial
Actual Study Start Date : May 2005
Actual Primary Completion Date : December 2012
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Telephone Genetic Counseling
Participants randomized to this arm will receive all genetic counseling via telephone.
Behavioral: Telephone Genetic Counseling
Participants will receive all genetic counseling via telephone

Active Comparator: Usual Care
Participants randomized to usual care will receive standard in-person genetic counseling.
Behavioral: Usual Care
subjects will receive standard in-person genetic counseling

Primary Outcome Measures :
  1. Uptake of BRCA1/BRCA2 mutation testing as measured by genetic test results at 3 and 6 months [ Time Frame: 6 months ]
  2. Knowledge assessed by genetic testing knowledge measure at post-counseling and 3 months [ Time Frame: 3 months ]
  3. Decision making as assessed by Decisional Conflict Satisfaction at post-counseling and 3 months [ Time Frame: 3 months ]
  4. Quality of life as assessed by SF-12 health survey at 3 and 6 months [ Time Frame: 6 months ]
  5. Distress as assessed by Impact of Events Scale Brief Symptom Inventory MICRA at 3 and 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Costs by cost measurement post-counseling [ Time Frame: 6 months ]
  2. Management behaviors as assessed by utilization of management options (e.g., mammography, surgery, and chemoprevention) at 6 and 12 months [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Must have at least 10% chance of carrying the BRCA1/BRCA2 gene, as defined by ≥ 1 of the following:

    • First-degree relative of affected family member with a 50% chance of inheriting a BRCA1/BRCA2 mutation
    • Second-degree relative with BRCA1/BRCA2 mutation with 25% risk of inheritance (parent deceased)
    • Obligate gene carrier or affected woman
  • Must live within 100 miles of the Lombardi Comprehensive Cancer Center
  • No more than 4 weeks since breast or ovarian cancer diagnosis
  • No metastatic or inflammatory breast cancer or ovarian cancer
  • No stage III breast or ovarian cancer while undergoing concurrent chemotherapy


  • No psychiatric illness or cognitive disorder that would preclude informed consent


  • No prior genetic counseling or testing for BRCA1 and/or BRCA2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00287898

Layout table for location information
United States, District of Columbia
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington, District of Columbia, United States, 20007
United States, Massachusetts
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115-6084
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, Vermont
Vermont Cancer Center at University of Vermont
Burlington, Vermont, United States, 05405-0110
Sponsors and Collaborators
Georgetown University
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Marc Schwartz, PhD Lombardi Comprehensive Cancer Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Georgetown University Identifier: NCT00287898    
Other Study ID Numbers: CDR0000450959
R01CA082346 ( U.S. NIH Grant/Contract )
R01CA108933 ( U.S. NIH Grant/Contract )
P30CA051008 ( U.S. NIH Grant/Contract )
First Posted: February 7, 2006    Key Record Dates
Last Update Posted: April 7, 2017
Last Verified: February 2017
Keywords provided by Georgetown University:
breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases